Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • New batch of Strides...

    New batch of Strides Pharma Ranitidine available for sale in Australia

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-25T11:33:55+05:30  |  Updated On 25 Oct 2019 11:33 AM IST
    New batch of Strides Pharma Ranitidine available for sale in Australia

    Out of the 135 batches of Ranitidine which were tested by TGA, 109 batches were found to have an NDMA level at or above the acceptable limit of 0.3 ppm. These batches include three batches from Strides supplied to its Australian partner Arrow, Strides said.


    NEW DELHI: Drug firm Strides Pharma Science on Wednesday said batches of Ranitidine tablets made by the company are now available for sale in Australia through its partner Arrow Pharmaceuticals Pvt Ltd.


    Strides had suspended the manufacturing and sale of its Ranitidine tablets for the US and Australia markets in September this year, given the concerns around impurity called N-Nitrosodimethylamine (NDMA) which is associated with an increased risk of cancer, the company said in a filing to the BSE.


    The Therapeutic Goods Administration (TGA), Australia, has now taken a decision to recall all Ranitidine products with levels of NDMA at or above 0.3 parts per million (ppm), while all batches with levels below 0.3 ppm are available for sale, it added.


    Out of the 135 batches of Ranitidine which were tested by TGA, 109 batches were found to have an NDMA level at or above the acceptable limit of 0.3 ppm. These batches include three batches from Strides supplied to its Australian partner Arrow, Strides said.


    Read Also: Strides Pharma suspends sale of Ranitidine tab in US


    Only 24 oral solid dosage batches were found to have levels of NDMA within the acceptable limit of 0.3 ppm of which 20 batches were manufactured by Strides for its partner Arrow with active pharmaceutical ingredient (API) supplied by Solara Active Pharma Sciences, it added.


    "Batches manufactured by Strides are now available for sale in Australia through its partner Arrow," Strides said.


    The company, however, did not specify the number of batches that are available for sale in Australia.


    Strides has submitted all requested data to the United States Food and Drug Administration (USFDA) in response to the information request received on Ranitidine. The company is awaiting further feedback from the USFDA on the NDMA limits for Ranitidine, it added.


    Read Also: CDSCO warns against Cancer Causing Impurities in anti-acidity drug Ranitidine, writes to state drug controllers

    Active Pharmaceutical IngredientAPIArrow PharmaceuticalsBSEN-nitrosodimethylamineNDMAnew batch of ranitidinepharmapharma companypharma newsranitidineRanitidine tabletsStridesStrides PharmaTGATherapeutic Goods AdministrationUnited States Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok